Get the Stockscreener App
9.52
5.84%
-0.59
Immunome Inc stock is traded at $9.52, with a volume of 655.45K.
It is down -5.84% in the last 24 hours and down -6.39% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
See More
Previous Close:
$10.11
Open:
$10.24
24h Volume:
655.45K
Relative Volume:
0.67
Market Cap:
$806.11M
Revenue:
-
Net Income/Loss:
$-106.81M
P/E Ratio:
-2.8747
EPS:
-3.3117
Net Cash Flow:
$-8.40M
1W Performance:
-8.46%
1M Performance:
-6.39%
6M Performance:
-37.37%
1Y Performance:
-56.75%
1-Day Range:
$9.51
$10.47
1-Week Range:
$9.51
$10.68
52-Week Range:
$8.97
$30.96
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
9.52 | 806.11M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
What Is Going On With Immunome Inc (NASDAQ: IMNM)? - Stocks Register
Immunome CFO receives relocation package, $400K in bonuses - MSN
Where are the Opportunities in (IMNM) - Stock Traders Daily
Three Bridge Wealth Advisors LLC Invests $293,000 in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome (NASDAQ:IMNM) Trading Down 6.7%Should You Sell? - MarketBeat
Immunome (NASDAQ:IMNM) Trading Up 11.7%Here's What Happened - MarketBeat
Q1 Earnings Forecast for Immunome Issued By Leerink Partnrs - MarketBeat
Immunome (NASDAQ:IMNM) Stock Price Down 6.7% – Here’s What Happened - Defense World
Philadelphia biotech firm backed by more than $130M names new CEO - The Business Journals
Pharma Veteran Behind Immunome's Success Story Named CEO of Rising Biotech Aro - StockTitan
Research Analysts Set Expectations for Immunome Q1 Earnings - Defense World
Checking in on Immunome Inc (IMNM) after recent insiders movement - Knox Daily
After The Stock Fell -1.45% Over The Week, Is Immunome Inc (NASDAQ: IMNM) Still A Buy? - Marketing Sentinel
Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall Purchases 150,000 Shares - MarketBeat
Short Interest in Immunome, Inc. (NASDAQ:IMNM) Rises By 12.2% - MarketBeat
Immunome Inc [IMNM] stock for 1,162,500 USD was acquired by SIEGALL CLAY B - Knox Daily
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Immunome (NASDAQ:IMNM) Shares Gap Up on Insider Buying Activity - MarketBeat
Following a 53% decline over last year, recent gains may please Immunome, Inc. (NASDAQ:IMNM) institutional owners - Simply Wall St
Deeper Dive: Understanding Immunome Inc (IMNM) Through its Various Ratios - The Dwinnex
Immunome (NASDAQ:IMNM) Shares Gap Up After Insider Buying Activity - Defense World
Tuesday 2/4 Insider Buying Report: IMNM - Nasdaq
Immunome Inc (IMNM) stock on the rise: An overview - US Post News
Immunome (NASDAQ:IMNM) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Insider Buying: Clay Siegall Acquires 150,000 Shares of Immunome Inc (IMNM) - GuruFocus.com
Immunome (NASDAQ:IMNM) Trading Up 7.2%Should You Buy? - MarketBeat
Scharf Investments LLC Takes Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome Closes Public Offering of Shares -January 31, 2025 at 04:13 pm EST - Marketscreener.com
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Business Wire
Immunome announces $125 million stock offering - MSN
Immunome Secures Massive $172.5M Capital Injection as Top Banks Rush to Join Offering - StockTitan
Vanguard Group Inc. Reduces Stake in Immunome Inc. - GuruFocus.com
Latham & Watkins Advises on Immunome’s Upsized Public Offering of Common Stock - Legal Desire News Network
Immunome stock tumbles after public offering pricing - MSN
Immunome Can Take The Fight To Competitors With Varegacestat (NASDAQ:IMNM) - Seeking Alpha
Immunome prices upsized public offering to raise $150M - MSN
Immunome stock tumbles after public offering pricing By Investing.com - Investing.com South Africa
IMNMImmunome, Inc. Latest Stock News & Market Updates - StockTitan
Immunome Prices $150 Million Stock Offering -January 30, 2025 at 03:53 am EST - Marketscreener.com
JPMorgan Chase & Co. Acquires 1,520 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome Announces Pricing of Upsized Public Offering of Common Stock - BioSpace
Immunome Announces Proposed Public Offering of Common Stock - BioSpace
Immunome's Massive $150M Capital Raise: Major Banks Back Biotech's Ambitious Plans - StockTitan
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunome Inc Stock (IMNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SIEGALL CLAY B | President and CEO |
Nov 21 '24 |
Buy |
9.54 |
66,057 |
630,263 |
485,693 |
| SIEGALL CLAY B | President and CEO |
Nov 22 '24 |
Buy |
9.78 |
33,943 |
331,918 |
519,636 |
| Lechleider Robert | Chief Medical Officer |
Nov 21 '24 |
Buy |
9.48 |
15,805 |
149,800 |
15,805 |
| Tsai Philip | Chief Technology Officer |
Nov 21 '24 |
Buy |
9.43 |
21,000 |
198,030 |
21,000 |
| Rosett Max | Chief Financial Officer |
Sep 19 '24 |
Option Exercise |
1.05 |
42,000 |
44,100 |
61,856 |
| Rosett Max | Chief Financial Officer |
Sep 19 '24 |
Sale |
16.01 |
14,380 |
230,224 |
47,476 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):